Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Net Cash Flow (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Net Cash Flow for 10 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow fell 95.05% to $2.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$34.9 million, a 219.44% decrease, with the full-year FY2025 number at -$34.9 million, down 219.44% from a year prior.
  • Net Cash Flow was $2.0 million for Q4 2025 at Rhythm Pharmaceuticals, up from -$83.7 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $108.5 million in Q2 2024 to a low of -$113.5 million in Q3 2024.
  • A 5-year average of -$2.3 million and a median of -$1.2 million in 2023 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: plummeted 193.85% in 2023, then skyrocketed 1668.92% in 2024.
  • Rhythm Pharmaceuticals' Net Cash Flow stood at -$33.1 million in 2021, then crashed by 73.32% to -$57.4 million in 2022, then soared by 92.48% to -$4.3 million in 2023, then soared by 1040.74% to $40.6 million in 2024, then plummeted by 95.05% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Net Cash Flow are $2.0 million (Q4 2025), -$83.7 million (Q3 2025), and $29.8 million (Q2 2025).